Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Evaluation of a new ultralow-dose radiation protocol for electrophysiological device implantation: A near-zero fluoroscopy approach for device implantation.

Eichenlaub M, Astheimer K, Minners J, Blum T, Restle C, Maring C, Schweitzer S, Thiel U, Neumann FJ, Arentz T, Lehrmann H.

Heart Rhythm. 2019 Sep 5. pii: S1547-5271(19)30672-1. doi: 10.1016/j.hrthm.2019.07.031. [Epub ahead of print]

2.

Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).

Wagner R, Randolph JT, Patel SV, Nelson L, Matulenko MA, Keddy R, Pratt JK, Liu D, Krueger AC, Donner PL, Hutchinson DK, Flentge C, Betebenner D, Rockway T, Maring CJ, Ng TI, Krishnan P, Pilot-Matias T, Collins C, Panchal N, Reisch T, Dekhtyar T, Mondal R, Stolarik DF, Gao Y, Gao W, Beno DA, Kati WM.

J Med Chem. 2018 May 10;61(9):4052-4066. doi: 10.1021/acs.jmedchem.8b00082. Epub 2018 Apr 23.

PMID:
29653491
3.

Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability.

Randolph JT, Krueger AC, Donner PL, Pratt JK, Liu D, Motter CE, Rockway TW, Tufano MD, Wagner R, Lim HB, Beyer JM, Mondal R, Panchal NS, Colletti L, Liu Y, Koev G, Kati WM, Hernandez LE, Beno DWA, Longenecker KL, Stewart KD, Dumas EO, Molla A, Maring CJ.

J Med Chem. 2018 Feb 8;61(3):1153-1163. doi: 10.1021/acs.jmedchem.7b01630. Epub 2018 Jan 25.

PMID:
29342358
4.

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.

Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02558-16. doi: 10.1128/AAC.02558-16. Print 2017 May.

5.

Discovery of fluorobenzimidazole HCV NS5A inhibitors.

Randolph JT, Flentge CA, Donner P, Rockway TW, Patel SV, Nelson L, Hutchinson DK, Mondal R, Mistry N, Reisch T, Dekhtyar T, Krishnan P, Pilot-Matias T, Stolarik DF, Beno DWA, Wagner R, Maring C, Kati WM.

Bioorg Med Chem Lett. 2016 Nov 15;26(22):5462-5467. doi: 10.1016/j.bmcl.2016.10.030. Epub 2016 Oct 13.

PMID:
27780635
6.

In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.

Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A, Maring C, Collins C.

Antimicrob Agents Chemother. 2015 Mar;59(3):1505-11. doi: 10.1128/AAC.04619-14. Epub 2014 Dec 22.

7.

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, Mistry N, Koev G, Reisch TJ, Mondal R, Pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins C, Wagner R, Kati WM.

J Med Chem. 2014 Mar 13;57(5):2047-57. doi: 10.1021/jm401398x. Epub 2014 Jan 15.

PMID:
24400777
8.

High potency improvements to weak aryl uracil HCV polymerase inhibitor leads.

Donner P, Randolph JT, Huang P, Wagner R, Maring C, Lim BH, Colletti L, Liu Y, Mondal R, Beyer J, Koev G, Marsh K, Beno D, Longenecker K, Pilot-Matias T, Kati W, Molla A, Kempf D.

Bioorg Med Chem Lett. 2013 Aug 1;23(15):4367-9. doi: 10.1016/j.bmcl.2013.05.078. Epub 2013 Jun 4.

PMID:
23791079
9.

Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif.

Krueger AC, Randolph JT, DeGoey DA, Donner PL, Flentge CA, Hutchinson DK, Liu D, Motter CE, Rockway TW, Wagner R, Beno DW, Koev G, Lim HB, Beyer JM, Mondal R, Liu Y, Kati WM, Longenecker KL, Molla A, Stewart KD, Maring CJ.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3487-90. doi: 10.1016/j.bmcl.2013.04.057. Epub 2013 May 1.

PMID:
23664214
10.

Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A.

DeGoey DA, Betebenner DA, Grampovnik DJ, Liu D, Pratt JK, Tufano MD, He W, Krishnan P, Pilot-Matias TJ, Marsh KC, Molla A, Kempf DJ, Maring CJ.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3627-30. doi: 10.1016/j.bmcl.2013.04.009. Epub 2013 Apr 10.

PMID:
23642966
11.

Identification of aryl dihydrouracil derivatives as palm initiation site inhibitors of HCV NS5B polymerase.

Liu Y, Lim BH, Jiang WW, Flentge CA, Hutchinson DK, Madigan DL, Randolph JT, Wagner R, Maring CJ, Kati WM, Molla A.

Bioorg Med Chem Lett. 2012 Jun 1;22(11):3747-50. doi: 10.1016/j.bmcl.2012.04.017. Epub 2012 Apr 10.

PMID:
22542020
12.

Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives.

Krueger AC, Madigan DL, Beno DW, Betebenner DA, Carrick R, Green BE, He W, Liu D, Maring CJ, McDaniel KF, Mo H, Molla A, Motter CE, Pilot-Matias TJ, Tufano MD, Kempf DJ.

Bioorg Med Chem Lett. 2012 Mar 15;22(6):2212-5. doi: 10.1016/j.bmcl.2012.01.096. Epub 2012 Feb 2.

PMID:
22342631
13.

Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moiety.

Hutchinson DK, Flentge CA, Donner PL, Wagner R, Maring CJ, Kati WM, Liu Y, Masse SV, Middleton T, Mo H, Montgomery D, Jiang WW, Koev G, Beno DW, Stewart KD, Stoll VS, Molla A, Kempf DJ.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1876-9. doi: 10.1016/j.bmcl.2010.12.067. Epub 2011 Jan 13.

PMID:
21316235
14.

Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.

Stewart KD, Huth JR, Ng TI, McDaniel K, Hutchinson RN, Stoll VS, Mendoza RR, Matayoshi ED, Carrick R, Mo H, Severin J, Walter K, Richardson PL, Barrett LW, Meadows R, Anderson S, Kohlbrenner W, Maring C, Kempf DJ, Molla A, Olejniczak ET.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):612-7. doi: 10.1016/j.bmcl.2009.11.076. Epub 2009 Nov 20.

PMID:
20004576
15.

Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.

Wagner R, Larson DP, Beno DW, Bosse TD, Darbyshire JF, Gao Y, Gates BD, He W, Henry RF, Hernandez LE, Hutchinson DK, Jiang WW, Kati WM, Klein LL, Koev G, Kohlbrenner W, Krueger AC, Liu J, Liu Y, Long MA, Maring CJ, Masse SV, Middleton T, Montgomery DA, Pratt JK, Stuart P, Molla A, Kempf DJ.

J Med Chem. 2009 Mar 26;52(6):1659-69. doi: 10.1021/jm8010965.

PMID:
19226162
16.

Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase.

Liu Y, Donner PL, Pratt JK, Jiang WW, Ng T, Gracias V, Baumeister S, Wiedeman PE, Traphagen L, Warrior U, Maring C, Kati WM, Djuric SW, Molla A.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3173-7. doi: 10.1016/j.bmcl.2008.04.068. Epub 2008 May 1.

PMID:
18479921
17.

Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase.

Donner PL, Xie Q, Pratt JK, Maring CJ, Kati W, Jiang W, Liu Y, Koev G, Masse S, Montgomery D, Molla A, Kempf DJ.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2735-8. doi: 10.1016/j.bmcl.2008.02.064. Epub 2008 Mar 4.

PMID:
18362072
18.

Synthesis of potent pyrrolidine influenza neuraminidase inhibitors.

Krueger AC, Xu Y, Kati WM, Kempf DJ, Maring CJ, McDaniel KF, Molla A, Montgomery D, Kohlbrenner WE.

Bioorg Med Chem Lett. 2008 Mar 1;18(5):1692-5. doi: 10.1016/j.bmcl.2008.01.048. Epub 2008 Jan 18.

PMID:
18242993
19.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives.

Krueger AC, Madigan DL, Green BE, Hutchinson DK, Jiang WW, Kati WM, Liu Y, Maring CJ, Masse SV, McDaniel KF, Middleton TR, Mo H, Molla A, Montgomery DA, Ng TI, Kempf DJ.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2289-92. Epub 2007 Jan 27.

PMID:
17300933
20.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring.

Rockway TW, Zhang R, Liu D, Betebenner DA, McDaniel KF, Pratt JK, Beno D, Montgomery D, Jiang WW, Masse S, Kati WM, Middleton T, Molla A, Maring CJ, Kempf DJ.

Bioorg Med Chem Lett. 2006 Jul 15;16(14):3833-8. Epub 2006 May 2.

PMID:
16650984
21.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides.

Krueger AC, Madigan DL, Jiang WW, Kati WM, Liu D, Liu Y, Maring CJ, Masse S, McDaniel KF, Middleton T, Mo H, Molla A, Montgomery D, Pratt JK, Rockway TW, Zhang R, Kempf DJ.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3367-70. Epub 2006 May 2.

PMID:
16650764
22.

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Mo H, Lu L, Pilot-Matias T, Pithawalla R, Mondal R, Masse S, Dekhtyar T, Ng T, Koev G, Stoll V, Stewart KD, Pratt J, Donner P, Rockway T, Maring C, Molla A.

Antimicrob Agents Chemother. 2005 Oct;49(10):4305-14.

23.

Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.

Maring CJ, Stoll VS, Zhao C, Sun M, Krueger AC, Stewart KD, Madigan DL, Kati WM, Xu Y, Carrick RJ, Montgomery DA, Kempf-Grote A, Marsh KC, Molla A, Steffy KR, Sham HL, Laver WG, Gu YG, Kempf DJ, Kohlbrenner WE.

J Med Chem. 2005 Jun 16;48(12):3980-90.

PMID:
15943472
24.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-heteroalkyl-4-hydroxyquinolon-3-yl-benzothiadiazines.

Pratt JK, Donner P, McDaniel KF, Maring CJ, Kati WM, Mo H, Middleton T, Liu Y, Ng T, Xie Q, Zhang R, Montgomery D, Molla A, Kempf DJ, Kohlbrenner W.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1577-82.

PMID:
15745800
25.

Design, synthesis, and structural analysis of inhibitors of influenza neuraminidase containing a 2,3-disubstituted tetrahydrofuran-5-carboxylic acid core.

Wang GT, Wang S, Gentles R, Sowin T, Maring CJ, Kempf DJ, Kati WM, Stoll V, Stewart KD, Laver G.

Bioorg Med Chem Lett. 2005 Jan 3;15(1):125-8.

PMID:
15582424
26.

Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series.

Stoll V, Stewart KD, Maring CJ, Muchmore S, Giranda V, Gu YG, Wang G, Chen Y, Sun M, Zhao C, Kennedy AL, Madigan DL, Xu Y, Saldivar A, Kati W, Laver G, Sowin T, Sham HL, Greer J, Kempf D.

Biochemistry. 2003 Jan 28;42(3):718-27.

PMID:
12534284
27.

Design, synthesis, and neuraminidase inhibitory activity of GS-4071 analogues that utilize a novel hydrophobic paradigm.

Hanessian S, Wang J, Montgomery D, Stoll V, Stewart KD, Kati W, Maring C, Kempf D, Hutchins C, Laver WG.

Bioorg Med Chem Lett. 2002 Dec 2;12(23):3425-9. Erratum in: Bioorg Med Chem Lett. 2003 May 19;13(10):1837.

PMID:
12419376
28.

In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.

Molla A, Kati W, Carrick R, Steffy K, Shi Y, Montgomery D, Gusick N, Stoll VS, Stewart KD, Ng TI, Maring C, Kempf DJ, Kohlbrenner W.

J Virol. 2002 Jun;76(11):5380-6.

29.

In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication.

Kati WM, Montgomery D, Carrick R, Gubareva L, Maring C, McDaniel K, Steffy K, Molla A, Hayden F, Kempf D, Kohlbrenner W.

Antimicrob Agents Chemother. 2002 Apr;46(4):1014-21.

30.

Novel alpha- and beta-amino acid inhibitors of influenza virus neuraminidase.

Kati WM, Montgomery D, Maring C, Stoll VS, Giranda V, Chen X, Laver WG, Kohlbrenner W, Norbeck DW.

Antimicrob Agents Chemother. 2001 Sep;45(9):2563-70.

31.

Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine.

Ng TI, Shi Y, Huffaker HJ, Kati W, Liu Y, Chen CM, Lin Z, Maring C, Kohlbrenner WE, Molla A.

Antimicrob Agents Chemother. 2001 Jun;45(6):1629-36.

32.

Acquired thromboatheromatous coarctation of the aorta: acquired coarctation of the aorta.

Sheikhzadeh A, Giannitsis E, Gehl HB, Maring C, Stierle U.

Int J Cardiol. 1999 Apr 30;69(1):87-91.

PMID:
10362378
33.

Antitumor activity of 9(R)-dihydrotaxane analogs.

Klein LL, Li L, Maring CJ, Yeung CM, Thomas SA, Grampovnik DJ, Plattner JJ.

J Med Chem. 1995 Apr 28;38(9):1482-92.

PMID:
7739007
34.

Synthesis and biological evaluation of C-3'-modified analogs of 9(R)-dihydrotaxol.

Li L, Thomas SA, Klein LL, Yeung CM, Maring CJ, Grampovnik DJ, Lartey PA, Plattner JJ.

J Med Chem. 1994 Aug 19;37(17):2655-63.

PMID:
7914927
35.

Synthesis and antimicrobial activities of 9(S)-N,N-dimethyl-amino-9-deoxo-10, 11,12,13-tetrahydroniddamycin.

Maring CJ, Freiberg LA, Lartey PA, Grampovnik DJ, Edwards CM, Hardy DJ, Swanson R, Fernandes PB.

J Antibiot (Tokyo). 1991 Apr;44(4):448-50. No abstract available.

36.

Synthesis and in vitro antibacterial properties of alkylspectinomycin analogs.

White DR, Maring CJ, Cain GA.

J Antibiot (Tokyo). 1983 Mar;36(3):339-42. No abstract available.

Supplemental Content

Loading ...
Support Center